{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:13:24Z","timestamp":1783635204768,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1038\/sj.bjc.6602604","type":"journal-article","created":{"date-parts":[[2005,5,31]],"date-time":"2005-05-31T12:21:40Z","timestamp":1117542100000},"page":"S14-S20","source":"Crossref","is-referenced-by-count":55,"title":["ZD6474 \u2013 clinical experience to date"],"prefix":"10.1038","volume":"92","author":[{"given":"J V","family":"Heymach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,6,3]]},"reference":[{"key":"BF6602604_CR1","doi-asserted-by":"publisher","first-page":"9101","DOI":"10.1158\/0008-5472.CAN-04-2360","volume":"64","author":"T Arao","year":"2004","unstructured":"Arao T, Fukumoto H, Takeda M, Tamura T, Saijo N, Nishio K (2004) Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Res 64: 9101\u20139104","journal-title":"Cancer Res"},{"key":"BF6602604_CR2","first-page":"1996","volume":"62","author":"CH Baker","year":"2002","unstructured":"Baker CH, Solorzano CC, Fidler IJ (2002) Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res 62: 1996\u20132003","journal-title":"Cancer Res"},{"key":"BF6602604_CR3","unstructured":"Briggs AD, Molofsky A, Wang J, Engelman P, Beaudry D, Prox D, Tracy S, Ryan AJ, Folkman J, Janne P, Johnson BE, Heymach JV (2005) Sensitivity of NSCLC cell lines bearing wild type and mutated EGFR to the VEGF\/EGFR inhibitor ZD6474. Proc Am Assoc Cancer Res 46: abstract 5833"},{"key":"BF6602604_CR4","first-page":"2926","volume":"60","author":"CJ Bruns","year":"2000","unstructured":"Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, Abbruzzese J, Traxler P, Buchdunger E, Radinsky R, Fidler IJ (2000) Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60: 2926\u20132935","journal-title":"Cancer Res"},{"key":"BF6602604_CR5","first-page":"1459","volume":"7","author":"F Ciardiello","year":"2001","unstructured":"Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco AR, Tortora G (2001) Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7: 1459\u20131465","journal-title":"Clin Cancer Res"},{"key":"BF6602604_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1053\/j.seminoncol.2003.08.013","volume":"30","author":"MA Cobleigh","year":"2003","unstructured":"Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, Reimann JD, Vassel A (2003) A phase I\/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30: 117\u2013124","journal-title":"Semin Oncol"},{"key":"BF6602604_CR7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337\u2013345","journal-title":"N Engl J Med"},{"key":"BF6602604_CR8","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1093\/jnci\/89.12.881","volume":"89","author":"G Fontanini","year":"1997","unstructured":"Fontanini G, Lucchi M, Vignati S, Mussi A, Ciardiello F, De Laurentiis M, De Placido S, Basolo F, Angeletti CA, Bevilacqua G (1997) Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst 89: 881\u2013886","journal-title":"J Natl Cancer Inst"},{"key":"BF6602604_CR9","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1200\/JCO.2000.18.12.2354","volume":"18","author":"FV Fossella","year":"2000","unstructured":"Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18: 2354\u20132362","journal-title":"J Clin Oncol"},{"key":"BF6602604_CR10","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","volume":"21","author":"M Fukuoka","year":"2003","unstructured":"Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21: 2237\u20132246","journal-title":"J Clin Oncol"},{"key":"BF6602604_CR11","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1200\/JCO.2001.19.3.843","volume":"19","author":"MS Gordon","year":"2001","unstructured":"Gordon MS, Margolin K, Talpaz M, Sledge Jr GW, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19: 843\u2013850","journal-title":"J Clin Oncol"},{"key":"BF6602604_CR12","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","volume":"22","author":"N Hanna","year":"2004","unstructured":"Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn Jr PA (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589\u20131597","journal-title":"J Clin Oncol"},{"key":"BF6602604_CR13","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2004.07.215","volume":"22","author":"RS Herbst","year":"2004","unstructured":"Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH (2004a) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial \u2013 INTACT 2. J Clin Oncol 22: 785\u2013794","journal-title":"J Clin Oncol"},{"key":"BF6602604_CR14","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1200\/JCO.2005.02.477","volume":"23","author":"RS Herbst","year":"2005","unstructured":"Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein Jr G, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A (2005) Phase I\/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1\/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23: 2544\u20132555","journal-title":"J Clin Oncol"},{"key":"BF6602604_CR15","doi-asserted-by":"crossref","unstructured":"Herbst RS, Prager D, Hermann R, Miller V, Fehrenbacher L, hoffman P (2004b) TRIBUTE \u2013 a phase III trial of erlotinib CCl (OSI-774) compared with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 23: (abstract 7011)","DOI":"10.1200\/jco.2004.22.14_suppl.7011"},{"key":"BF6602604_CR16","doi-asserted-by":"crossref","unstructured":"Heymach JV, Dong R-P, Dimery I, Wheeler C, Fidias P, Lu C, Johnson B, Herbst R (2004) ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: Results of the run-in phase of a two-part, randomized phase II study. Proc Am Soc Clin Oncol 23: (abstract 3051)","DOI":"10.1200\/jco.2004.22.90140.3051"},{"key":"BF6602604_CR17","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335\u20132342","journal-title":"N Engl J Med"},{"key":"BF6602604_CR18","unstructured":"Hurwitz H, Holden SN, Eckhardt SG, Rosenthal M, de Boer R, Rischin D, Green M, Basser R (2002) Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors. Proc Am Soc Clin Oncol 21: (abstract 325)"},{"key":"BF6602604_CR19","doi-asserted-by":"crossref","unstructured":"Johnson B, Ma P, West H, Kerr R, Prager D, Sandler A, Herbst RS, Stewart DJ, Dimery I, Heymach JV (2005) Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC. Proc Am Soc Clin Oncol 24: (abstract 7102)","DOI":"10.1200\/jco.2005.23.16_suppl.7102"},{"key":"BF6602604_CR20","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","volume":"22","author":"DH Johnson","year":"2004","unstructured":"Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore III RF, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22: 2184\u20132191","journal-title":"J Clin Oncol"},{"key":"BF6602604_CR21","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1053\/j.seminoncol.2003.12.015","volume":"31","author":"RS Kerbel","year":"2004","unstructured":"Kerbel RS (2004) Antiangiogenic drugs and current strategies for the treatment of lung cancer. Semin Oncol 31: 54\u201360","journal-title":"Semin Oncol"},{"key":"BF6602604_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1200\/JCO.2001.19.1.265","volume":"19","author":"EL Korn","year":"2001","unstructured":"Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC (2001) Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol 19: 265\u2013272","journal-title":"J Clin Oncol"},{"key":"BF6602604_CR23","doi-asserted-by":"crossref","unstructured":"Kovacs MJ, Reece DE, Marcellus D, Meyer R, Matthews S, Dong R-P, Eisenhauer EA (2004) A phase II study of ZD6474, a vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in patients with relapsed multiple myeloma (MM). Blood 104 (11 Suppl): abstract 3464","DOI":"10.1182\/blood.V104.11.3464.3464"},{"key":"BF6602604_CR24","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S1010-7940(97)00218-2","volume":"12","author":"M Lucchi","year":"1997","unstructured":"Lucchi M, Fontanini G, Mussi A, Vignati S, Ribechini A, Menconi GF, Bevilacqua G, Angeletti CA (1997) Tumor angiogenesis and biologic markers in resected stage I NSCLC. Eur J Cardiothorac Surg 12: 535\u2013541","journal-title":"Eur J Cardiothorac Surg"},{"key":"BF6602604_CR25","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129\u20132139","journal-title":"N Engl J Med"},{"key":"BF6602604_CR26","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/0003-4975(94)90117-1","volume":"57","author":"P Macchiarini","year":"1994","unstructured":"Macchiarini P, Fontanini G, Dulmet E, de MV, Chapelier AR, Cerrina J, Ladurie FL, Dartevelle PG (1994) Angiogenesis: an indicator of metastasis in non-small cell lung cancer invading the thoracic inlet. Ann Thorac Surg 57: 1534\u20131539","journal-title":"Ann Thorac Surg"},{"key":"BF6602604_CR27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0140-6736(92)93217-B","volume":"340","author":"P Macchiarini","year":"1992","unstructured":"Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA (1992) Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 340: 145\u2013146","journal-title":"Lancet"},{"key":"BF6602604_CR28","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/sj.bjc.6600551","volume":"87","author":"AP Meert","year":"2002","unstructured":"Meert AP, Paesmans M, Martin B, Delmotte P, Berghmans T, Verdebout JM, Lafitte JJ, Mascaux C, Sculier JP (2002) The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 87: 694\u2013701","journal-title":"Br J Cancer"},{"key":"BF6602604_CR29","unstructured":"Miller KD, Trigo JM, Stone A, Wheeler C, Barge A, Sledge GW, Baselga J (2004) A phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer (MBC). Breast Cancer Res Treat 88 (Suppl): abstract 6060"},{"key":"BF6602604_CR30","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497\u20131500","journal-title":"Science"},{"key":"BF6602604_CR31","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1023\/A:1016045012466","volume":"4","author":"H Pavlakovic","year":"2001","unstructured":"Pavlakovic H, Havers W, Schweigerer L (2001) Multiple angiogenesis stimulators in a single malignancy: implications for anti-angiogenic tumour therapy. Angiogenesis 4: 259\u2013262","journal-title":"Angiogenesis"},{"key":"BF6602604_CR32","first-page":"963","volume":"57","author":"M Relf","year":"1997","unstructured":"Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris AL (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57: 963\u2013969","journal-title":"Cancer Res"},{"key":"BF6602604_CR33","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1056\/NEJMoa011954","volume":"346","author":"JH Schiller","year":"2002","unstructured":"Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92\u201398","journal-title":"N Engl J Med"},{"key":"BF6602604_CR34","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","volume":"18","author":"FA Shepherd","year":"2000","unstructured":"Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O\u2019Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095\u20132103","journal-title":"J Clin Oncol"},{"key":"BF6602604_CR35","doi-asserted-by":"publisher","first-page":"7022","DOI":"10.1200\/jco.2004.22.14_suppl.7022","volume":"22","author":"FA Shepherd","year":"2004","unstructured":"Shepherd FA, Pereira J, Ciuleanu TE, Tan EH, Hirsh V, Thongprasert S, Bezjak A, Tu D, Santabarbara P, Seymour L (2004) A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. Proc Am Soc Clin Oncol 22: 7022","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6602604_CR36","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1200\/JCO.2001.19.6.1848","volume":"19","author":"RM Simon","year":"2001","unstructured":"Simon RM, Steinberg SM, Hamilton M, Hildesheim A, Khleif S, Kwak LW, Mackall CL, Schlom J, Topalian SL, Berzofsky JA (2001) Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol 19: 1848\u20131854","journal-title":"J Clin Oncol"},{"key":"BF6602604_CR37","first-page":"3369","volume":"61","author":"CJ Sweeney","year":"2001","unstructured":"Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, Sledge Jr GW (2001) The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 61: 3369\u20133372","journal-title":"Cancer Res"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6602604.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602604","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602604.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:16:36Z","timestamp":1684412196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6602604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":37,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["BF6602604"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6602604","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}